Chronic Urticaria Suspected to be Caused by a 13.5 mg Levonorgestrel Intrauterine Device (Skyla®)
- PMID: 37609103
- PMCID: PMC10440827
- DOI: 10.7759/cureus.42287
Chronic Urticaria Suspected to be Caused by a 13.5 mg Levonorgestrel Intrauterine Device (Skyla®)
Abstract
Chronic urticaria (CU) is a hive-like rash lasting over six weeks. Common associations include low vitamin D, thyroid autoantibodies, and Helicobacter pylori (H. pylori) infection, among others. Progesterone has been documented to trigger CU, by endogenous or exogenous progesterone. The use of intrauterine devices (IUDs) has been a popular source of birth control, with many containing progesterone. Although rarely reported, some patients have been seen to have an urticarial reaction after implantation of an IUD. Here, we present a case of a patient with progesterone-induced chronic urticaria, likely triggered by implantation of a 13.5 mg intrauterine device implant (Skyla®, Bayer, Whippany, NJ, USA). To the best of our knowledge, this is the first case to report the association between Skyla® and chronic urticaria.
Keywords: allergy; autoimmune progesterone dermatitis; chronic urticaria; immunology; intrauterine device; iud; levonorgestrel; progesterone; rash; skyla.
Copyright © 2023, Ganguli et al.
Conflict of interest statement
The authors have declared that no competing interests exist.
Similar articles
-
Endometrial morphological changes in IUD users: a review.Contraception. 1987 Jul;36(1):1-10. doi: 10.1016/0010-7824(87)90057-6. Contraception. 1987. PMID: 3117492 Review.
-
[The role of copper-releasing intrauterine device or levonorgestrel-releasing intrauterine system on uterine bleeding and iron status (prospective study of 8 years)].Minerva Ginecol. 2002 Jun;54(3):271-8. Minerva Ginecol. 2002. PMID: 12063443 Italian.
-
Intrauterine devices: an effective alternative to oral hormonal contraception.Prescrire Int. 2009 Jun;18(101):125-30. Prescrire Int. 2009. PMID: 19637436
-
Extended use of the intrauterine device: a literature review and recommendations for clinical practice.Contraception. 2014 Jun;89(6):495-503. doi: 10.1016/j.contraception.2014.02.011. Epub 2014 Feb 26. Contraception. 2014. PMID: 24679478 Review.
-
Two years' experience with two levonorgestrel-releasing intrauterine devices and one copper-releasing intrauterine device: a randomized comparative performance study.Fertil Steril. 1983 Feb;39(2):187-92. Fertil Steril. 1983. PMID: 6401636 Clinical Trial.
References
-
- Acute urticaria: an extremely rare adverse effect of levonorgestrel-releasing intrauterine system as a possible manifestation of progestogen hypersensitivity syndrome. Emeryk-Maksymiuk J, Grzywa-Celińska A, Woźniak S, Szkodziak P, Szczyrek M. Postepy Dermatol Alergol. 2018;35:530–531. - PMC - PubMed
-
- Pathogenesis of chronic urticaria. Kaplan AP, Greaves M. Clin Exp Allergy. 2009;39:777–787. - PubMed
-
- Hypersensitivity to Mirena--a rare complication. Pereira A, Coker A. https://www.tandfonline.com/doi/abs/10.1080/0144361021000082665 J Obstet Gynaecol. 2003;23:81. - PubMed
-
- Autoimmune progesterone dermatitis: case report with history of urticaria, petechiae and palpable pinpoint purpura triggered by medical abortion. Mbonile L. S Afr Med J. 2016;106:48–50. - PubMed
-
- Intrauterine uterine contraception and chronic urticaria: a case series. Wunschel J, Poole JA. Ann Allergy Asthma Immunol. 2017;118:378–380. - PubMed
Publication types
LinkOut - more resources
Full Text Sources